CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$54.01 USD
-1.37 (-2.47%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $54.16 +0.15 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.01 USD
-1.37 (-2.47%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $54.16 +0.15 (0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Zacks News
CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1.18% and -78.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.
CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.
Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.
Earnings Preview: CRISPR Therapeutics AG (CRSP) Q3 Earnings Expected to Decline
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex's (VRTX) Early Type I Diabetes Study Data Promising
by Zacks Equity Research
Vertex's (VRTX) single infusion drug candidate, VX-880, for type I diabetes shows restoration of insulin production and robust improvements in multiple measures in a phase I/II study
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies
by Indrajit Bandyopadhyay
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease
by Zacks Equity Research
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.
Why CRISPR Therapeutics (CRSP) Stock is Falling Today
by Madeleine Johnson
Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.
Editas (EDIT) Down on Initial Data From Eye Disease Study
by Zacks Equity Research
Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.
Why CRISPR Therapeutics AG (CRSP) is a Top Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed at $120.74 in the latest trading session, marking a -0.59% move from the prior day.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.07, marking a +0.56% move from the previous day.
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
by Zacks Equity Research
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to Watch
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why
by Zacks Equity Research
Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.
How Are Genomics ETFs Responding to Q2 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.
CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.